STUDY TITLE	**RELAX-ASIA - A multicenter , randomized , double-blind , placebo-controlled phase III study to evaluate the efficacy , safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients**
STUDY POPULATION	**Patient admitted with Heart Failure**
PRINCIPAL INVESTIGATOR	Dato' Dr. David Chew Soon Ping
STUDY COORDINATOR	Tengku Azura Tengku Saibon Contact number 03 – 2617 8200 ext 8342
START DATE	17 Aug 2014
END DATE	July 2017

INCLUSION	General Inclusion :-
	• Male or female subjects age 18 years or more , body weight 30kg or more and 160 kg or less
	• Written informed consent must be obtained before any study – specific assessment is performed
	• Hospitalized for AHF :
	  ○ Persistent dyspnea at rest or with minimal exertion at screening and at the time randomization
	  ○ Pulmonary congestion on CXR
	  ○ BNP 350 pg/mL or more or NT-proBNP 1400 pg/mL or more
	• SBP 125 mmHg or more at the start and at the end of screening
	• Able to be randomized within 16 hours from presentation to the hospital, including casualty and outpatient clinic
	• Received IV Lasix of at least 40 mg total (or equivalent) at any time between presentation
	• Impaired renal functions defined as an eGFR between presentation and randomization of 25 or more and 75 ml/min/1.73m2 or less calculated using the sMDRD formula
	• Dyspnea primarily due to non-cardiac causes such as acute or chronic respiratory
	• Temperature more than 38.5 or sepsis or active and clinically significant infection requiring IV antibiotic or kwon presence or evidence of HIV

EXCLUSION	General Exclusion :- • Dyspnea primarily due to non-cardiac causes such as acute or chronic respiratory • Temperature more than 38.5 or sepsis or active and clinically significant infection requiring IV antibiotic or kwon presence or evidence of HIV • Clinical evidence of ACS or within 30 days prior to enrollment • AHF due to significant arrhythmias • Patient with hematocrit less than 25% • COPD • Plan for mechanical ventilation • Hepatic disease • Major surgery , including ICD and CRT within 30 days prior • Any organ transplant • Pregnant • Subjects participating in another clinical investigation